N/A
Completed N=336
Assessment of Myocardial Ischemic-Reperfusion Injury During Off- and On- Pump CABG
Heart Failure · Coronary Artery Disease · Ischemic Reperfusion Injury · CABG
Source: ClinicalTrials.gov NCT03050489 ↗
Enrolled (actual)
336
Serious AEs
9.4%
Results posted
Jan 2023
Primary outcomePrimary: Myeloperoxidase — 184.3; 66.5; 144.71 g/L
Summary
Assessment of myocardial ischemic-reperfusion injury during off- and on- pump CABG.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Myeloperoxidase |
184.3; 66.5; 144.71 | — |
| SECONDARY Low Cardiac Output Syndrome |
15; 15; 1 | — |
| SECONDARY Length of Stay in Intensive Care Unit |
2; 2; 2 | — |
| SECONDARY Length of Stay in Hospital |
13; 12; 13 | — |
| SECONDARY Cumulative Dose of Inotrope |
0; 0; 0 | — |
| SECONDARY Days of Administration of Inotrope |
0; 0; 0 | — |
| SECONDARY Pulmonary Ventilation |
1; 1; 1 | — |
| SECONDARY Systolic Function |
62; 62; 63 | — |
| SECONDARY Diastolic Function |
106.0; 97.0; 109.5 | — |
| SECONDARY Number of Participants With Reoperation |
1; 1; 0 | — |
| SECONDARY Renal Dysfunction |
70; 49; 7 | — |
| SECONDARY Atrial Fibrillation. |
27; 26; 8 | — |
Eligibility Criteria
Inclusion Criteria
- ischemic heart disease
Exclusion Criteria
- valve disease
- diabetes millitus
Data sourced from ClinicalTrials.gov (NCT03050489). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.